BACKGROUND: Malignant mesothelioma is a rare, insidious, and aggressive tumor arising from the mesothelial surface of pleural and peritoneal cavities, the pericardium, or the tunica vaginalis, with an increasing incidence worldwide, high misdiagnosis rate, and overall negative prognosis. A total of 20% of all cases is peritoneum in origin. METHODS: The present study is a review of literatures focusing on the advances in epidemiology, clinical presentations, radiological features, diagnosis, misdiagnosis, management, and prognostic factors of malignant peritoneal mesothelioma (MPM) occurred in the past decades. RESULTS: Asbestos, SV40, and radiation exposures have been demonstrated to be correlated with the pathogenesis of MPM. The main presentations are abdominal distension and pain. Computed tomography (CT), magnetic resonance imaging (MRI), and positron-emission tomography (PET) play an important role in the preoperative imaging and staging. Definitive diagnosis is made on the basis of immunohistochemistry. Prognostic factors have been identified and verified. Negative indicators include advanced age, male gender, poor performance status, non-epithelial histology, and absence of surgery. The management of MPM has evolved from single chemotherapy to multimodality treatment of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC), chemotherapy, radiotherapy, and immunotherapy. Promising results have been achieved after a combined treatment of CRS and HIPEC, with an elevated median survival time of 29.5-92 months and a 5-year survival rate of 39-63%. CONCLUSIONS: CRS and HIPEC represent the standard treatment strategy for selected patients with MPM, and patients with unresectable tumors can benefit from the combined treatment of chemotherapy, radiotherapy, and immunotherapy.
BACKGROUND:Malignant mesothelioma is a rare, insidious, and aggressive tumor arising from the mesothelial surface of pleural and peritoneal cavities, the pericardium, or the tunica vaginalis, with an increasing incidence worldwide, high misdiagnosis rate, and overall negative prognosis. A total of 20% of all cases is peritoneum in origin. METHODS: The present study is a review of literatures focusing on the advances in epidemiology, clinical presentations, radiological features, diagnosis, misdiagnosis, management, and prognostic factors of malignant peritoneal mesothelioma (MPM) occurred in the past decades. RESULTS: Asbestos, SV40, and radiation exposures have been demonstrated to be correlated with the pathogenesis of MPM. The main presentations are abdominal distension and pain. Computed tomography (CT), magnetic resonance imaging (MRI), and positron-emission tomography (PET) play an important role in the preoperative imaging and staging. Definitive diagnosis is made on the basis of immunohistochemistry. Prognostic factors have been identified and verified. Negative indicators include advanced age, male gender, poor performance status, non-epithelial histology, and absence of surgery. The management of MPM has evolved from single chemotherapy to multimodality treatment of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC), chemotherapy, radiotherapy, and immunotherapy. Promising results have been achieved after a combined treatment of CRS and HIPEC, with an elevated median survival time of 29.5-92 months and a 5-year survival rate of 39-63%. CONCLUSIONS: CRS and HIPEC represent the standard treatment strategy for selected patients with MPM, and patients with unresectable tumors can benefit from the combined treatment of chemotherapy, radiotherapy, and immunotherapy.
Authors: Mary E Hesdorffer; John A Chabot; Mary Louise Keohan; Karen Fountain; Susan Talbot; Michelle Gabay; Catherine Valentin; Shing M Lee; Robert N Taub Journal: Am J Clin Oncol Date: 2008-02 Impact factor: 2.339
Authors: Andrew L Feldman; Steven K Libutti; James F Pingpank; David L Bartlett; Tatiana H Beresnev; Sharon M Mavroukakis; Seth M Steinberg; David J Liewehr; David E Kleiner; H Richard Alexander Journal: J Clin Oncol Date: 2003-12-15 Impact factor: 44.544
Authors: S Pitarque; R Clèries; J M Martínez; G López-Abente; M Kogevinas; F G Benavides Journal: Occup Environ Med Date: 2007-09-21 Impact factor: 4.402
Authors: Edward A Levine; John H Stewart; Perry Shen; Gregory B Russell; Brian L Loggie; Konstantinos I Votanopoulos Journal: J Am Coll Surg Date: 2013-12-21 Impact factor: 6.113
Authors: Sivaveera Kandasamy; Gautam Adhikary; Ellen A Rorke; Joseph S Friedberg; McKayla B Mickle; H Richard Alexander; Richard L Eckert Journal: Mol Cancer Res Date: 2019-11-15 Impact factor: 5.852
Authors: Pedram Argani; Derrick W Q Lian; Abbas Agaimy; Markus Metzler; Sara E Wobker; Andres Matoso; Jonathan I Epstein; Yun-Shao Sung; Lei Zhang; Cristina R Antonescu Journal: Am J Surg Pathol Date: 2021-05-01 Impact factor: 6.298
Authors: David Larson; Amy Powers; Jean-Paul Ambrosi; Mika Tanji; Andrea Napolitano; Erin G Flores; Francine Baumann; Laura Pellegrini; Cormac J Jennings; Brenda J Buck; Brett T McLaurin; Doug Merkler; Cleo Robinson; Paul Morris; Meral Dogan; A Umran Dogan; Harvey I Pass; Sandra Pastorino; Michele Carbone; Haining Yang Journal: J Toxicol Environ Health B Crit Rev Date: 2016 Impact factor: 6.393